ZombieHealthcare
What Happened to Citius Oncology?
Ticker: CTORSPAC Year: 2022
Return
-93.7%
Current Price
$0.63
Peak Price
$49
Trust Size
$110M
Summary
Citius Oncology is a biopharmaceutical company focused on developing anti-cancer treatments, including its lead product LYMPHIR for the treatment of cutaneous T-cell lymphoma.
What Happened
Citius Oncology was spun off from Citius Pharmaceuticals and trades under CTOR. The company's LYMPHIR (denileukin diftitox) received FDA approval for the treatment of relapsed or refractory cutaneous T-cell lymphoma. Despite the FDA approval, the stock has declined and the company has reported going concern warnings as it works to commercialize the treatment.
Timeline
2022-03-08
S-1 Registration Filed